Both Aubagio and Bexagliflozin offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Aubagio and Bexagliflozin have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Both Aubagio and Bexagliflozin have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Bexagliflozin offers greater flexibility with different delivery forms, making it suitable for patients with specific preferences or medical needs.

Bexagliflozin is better for patients with cardiovascular or diabetes-related issues, as it has fewer interactions with other medications.

Bexagliflozin is better suited for chronic conditions, offering longer-lasting effects and a favorable safety profile for long-term use. Its flexibility in administration makes it a strong option for various patient needs.